Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, to market a generic equivalent of Toviaz® Extended-Release Tablets, 4 mg and 8 mg, of Pfizer Inc. The product will be manufactured at Lupin's facility in Goa, India. Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,844 INR | +0.68% | +3.67% | +39.41% |
06:01am | Lupin Sells US Commercial Women's Health Specialty Business to Evofem Biosciences | MT |
07-15 | Lupin Gets Establishment Inspection Report from US FDA After Dabhasa Unit, Inspection | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.41% | 10B | |
+62.27% | 856B | |
+38.95% | 631B | |
-4.09% | 359B | |
+15.37% | 325B | |
+9.50% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+16.25% | 177B | |
+2.38% | 165B |
- Stock Market
- Equities
- LUPIN Stock
- News Lupin Limited
- Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets